246 related articles for article (PubMed ID: 8031044)
1. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.
Payne DJ; Cramp R; Winstanley DJ; Knowles DJ
Antimicrob Agents Chemother; 1994 Apr; 38(4):767-72. PubMed ID: 8031044
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT
Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615
[TBL] [Abstract][Full Text] [Related]
3. Different intermediate populations formed by tazobactam, sulbactam, and clavulanate reacting with SHV-1 beta-lactamases: Raman crystallographic evidence.
Kalp M; Totir MA; Buynak JD; Carey PR
J Am Chem Soc; 2009 Feb; 131(6):2338-47. PubMed ID: 19161282
[TBL] [Abstract][Full Text] [Related]
4. Interaction of clavulanic acid, sulbactam and cephamycin antibiotics with beta-lactamases.
Grace ME; Fu KP; Gregory FJ; Hung PP
Drugs Exp Clin Res; 1987; 13(3):145-8. PubMed ID: 3040368
[TBL] [Abstract][Full Text] [Related]
5. Effect of clavulanic acid, sulbactam and tazobactam on three different beta-lactamases from Bacteroides uniformis, Clostridium butyricum and Fusobacterium nucleatum.
Hedberg M; Lindqvist L; Tunér K; Nord CE
J Antimicrob Chemother; 1992 Jul; 30(1):17-25. PubMed ID: 1331018
[TBL] [Abstract][Full Text] [Related]
6. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
Piddock LJ; Jin YF; Turner HL
J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105
[TBL] [Abstract][Full Text] [Related]
7. Beta-lactamase inhibition by acetylmethylene penicillanic acid compared to that of clavulanate and sulbactam.
Chin NX; McElrath MJ; Neu HC
Chemotherapy; 1988; 34(4):318-25. PubMed ID: 2850139
[TBL] [Abstract][Full Text] [Related]
8. Effect of beta-lactamase inhibitors on beta-lactamases from anaerobic bacteria.
Hedberg M; Lindqvist L; Tunér K; Nord CE
Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1100-4. PubMed ID: 1338315
[TBL] [Abstract][Full Text] [Related]
9. Comparative in-vitro activities of GD-40 and other beta-lactamase inhibitors against TEM-1 and SHV-2 beta-lactamases.
Danelon G; Mascaretti O; Radice M; Power P; Calcagno ML; Mata EG; Gutkind G
J Antimicrob Chemother; 1998 Feb; 41(2):313-5. PubMed ID: 9533481
[No Abstract] [Full Text] [Related]
10. Effect of pH on activities of novel beta-lactamases and beta-lactamase inhibitors against these beta-lactamases.
Ohsuka S; Arakawa Y; Horii T; Ito H; Ohta M
Antimicrob Agents Chemother; 1995 Aug; 39(8):1856-8. PubMed ID: 7486932
[TBL] [Abstract][Full Text] [Related]
11. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases.
Giakkoupi P; Tzelepi E; Legakis NJ; Tzouvelekis LS
J Antimicrob Chemother; 1999 Jan; 43(1):23-9. PubMed ID: 10381097
[TBL] [Abstract][Full Text] [Related]
12. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
[TBL] [Abstract][Full Text] [Related]
13. Selection of variants of the TEM-1 beta-lactamase, encoded by a plasmid of clinical origin, with increased resistance to beta-lactamase inhibitors.
Thomson CJ; Amyes SG
J Antimicrob Chemother; 1993 May; 31(5):655-64. PubMed ID: 8392995
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli.
Blazquez J; Baquero MR; Canton R; Alos I; Baquero F
Antimicrob Agents Chemother; 1993 Oct; 37(10):2059-63. PubMed ID: 8257123
[TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
Gatermann S; Marre R
Infection; 1991; 19(2):106-9. PubMed ID: 1646771
[TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
Sader HS; Tosin I; Sejas L; Miranda E
Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
[TBL] [Abstract][Full Text] [Related]
17. High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 {beta}-lactamase.
Padayatti PS; Helfand MS; Totir MA; Carey MP; Carey PR; Bonomo RA; van den Akker F
J Biol Chem; 2005 Oct; 280(41):34900-7. PubMed ID: 16055923
[TBL] [Abstract][Full Text] [Related]
18. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.
Jacobs MR; Aronoff SC; Johenning S; Shlaes DM; Yamabe S
Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin.
Higashitani F; Hyodo A; Ishida N; Inoue M; Mitsuhashi S
J Antimicrob Chemother; 1990 Apr; 25(4):567-74. PubMed ID: 2161820
[TBL] [Abstract][Full Text] [Related]
20. Interaction of beta-lactamase inhibitors with various beta-lactamases.
Cullmann W
Chemotherapy; 1990; 36(3):200-8. PubMed ID: 2159863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]